Cargando…

Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs

BACKGROUND: Sequential monotherapies of nucleotide analogs used in chronic hepatitis B treatment can lead to the selection of a resistance mutation to each antiviral drug. CASE PRESENTATION: A patient with chronic hepatitis B was successively treated with lamivudine monotherapy, lamivudine-adefovir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larrat, Sylvie, Hilleret, Marie-Noëlle, Germi, Raphaele, Lupo, Julien, Nicod, Sandrine, Zarski, Jean-Pierre, Seigneurin, Jean-Marie, Morand, Patrice
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322943/ https://www.ncbi.nlm.nih.gov/pubmed/18336716 http://dx.doi.org/10.1186/1476-5926-7-3

Ejemplares similares

De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)

Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus
por: Kim, Kang Mo, et al.
Publicado: (2005)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
por: Lian, Jiang-Shan, et al.
Publicado: (2019)

Evaluation of six commercial SARS-CoV-2 rapid antigen tests in nasopharyngeal swabs: Better knowledge for better patient management?
por: Andreani, Julien, et al.
Publicado: (2021)

Virological Markers in Epstein–Barr Virus-Associated Diseases
por: Lupo, Julien, et al.
Publicado: (2023)

A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol
por: Xie, Wen, et al.
Publicado: (2011)

Low-dose adefovir dipivoxil–induced hypophosphatemia osteomalacia in five chronic hepatitis B virus–infected patients. Is low-dose adefovir dipivoxil–induced nephrotoxicity completely reversible?
por: Qian, Yan-Ying, et al.
Publicado: (2019)

Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection
por: Zhong, Jian-Hong, et al.
Publicado: (2016)

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
por: Jung, Young Kul, et al.
Publicado: (2011)

Effect of Hepatitis B Virus Genotypes on the Efficacy of Adefovir Dipivoxil Antiviral Therapy
por: Wen, Zhili, et al.
Publicado: (2014)

Fanconi syndrome induced by adefovir dipivoxil: a case report and clinical review
por: Song, Kaixin, et al.
Publicado: (2020)

Follow-Up of Adefovir Dipivoxil Induced Osteomalacia: Clinical Characteristics and Genetic Predictors
por: Zhao, Jiao, et al.
Publicado: (2021)

Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA
por: Gong, Xubo, et al.
Publicado: (2022)

Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine
por: Jean-Pierre, Vincent, et al.
Publicado: (2021)

Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000–2016
por: Fourcade, Grégoire, et al.
Publicado: (2017)

Effect of adefovir dipivoxil on T cell immune function in the treatment of chronic hepatitis B and hepatocirrhosis
por: Tian, Liting, et al.
Publicado: (2016)

Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil
por: Zhu, Sheng, et al.
Publicado: (2017)

Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis
por: Liu, Fen, et al.
Publicado: (2014)

Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure
por: Yang, Jiahong, et al.
Publicado: (2015)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
por: Shi, Hong, et al.
Publicado: (2017)

Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Naïve Chronic Hepatitis B Patients at 48 Weeks
por: Wang, Li-Chun, et al.
Publicado: (2011)

Pathologic Femoral Neck Fracture Due to Fanconi Syndrome Induced by Adefovir Dipivoxil Therapy for Hepatitis B
por: Lee, Yoon-Suk, et al.
Publicado: (2016)

Deep Sequencing Analysis of HBV Genotype Shift and Correlation with Antiviral Efficiency during Adefovir Dipivoxil Therapy
por: Wang, Yuwei, et al.
Publicado: (2015)

Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients
por: Korkmaz, Pinar, et al.
Publicado: (2014)

Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation
por: Voss, Linda, et al.
Publicado: (2021)

Kushenin Combined with Adefovir Dipivoxil or Entecavir for Chronic Hepatitis B: A Systematic Review and Meta-Analysis
por: Liao, Qingying, et al.
Publicado: (2021)

Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report
por: Tanaka, Motoyuki, et al.
Publicado: (2012)

Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis
por: Luo, Qing, et al.
Publicado: (2016)

Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes
por: Alqahtani, Tariq, et al.
Publicado: (2023)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
por: Kim, Jeong Han, et al.
Publicado: (2013)

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
por: Shakado, Satoshi, et al.
Publicado: (2008)

Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation
por: Lee, Jae Geun, et al.
Publicado: (2015)

Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series
por: Chen, Nan, et al.
Publicado: (2018)

Detection of rtN236T mutation associated with adefovir dipivoxil resistance in Hepatitis B infected patients with YMDD mutations in Tehran
por: Monavari, Seyed Hamidreza, et al.
Publicado: (2013)

Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: A STROBE-compliant article
por: Xu, Yong, et al.
Publicado: (2018)

A Simple and Specific Stability- Indicating RP-HPLC Method for Routine Assay of Adefovir Dipivoxil in Bulk and Tablet Dosage Form
por: Darsazan, Bahar, et al.
Publicado: (2017)

The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection
por: He, Linye, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nmbcukia7htq92ap3igdbvm5vf